HC Wainwright Raises Innoviva Price Target to $45.00, Boosts Buy Rating

HC Wainwright & Co. has raised the price target for Innoviva (INVA) to $45.00, a 12.50% increase from the prior target, and maintained its "Buy" rating. Analyst Raghuram Selvaraju expressed confidence in the company's market performance and growth potential. The average target price for INVA is $40.33, with a high estimate of $55.00 and a low estimate of $26.00, indicating a potential upside of 119.92% from the current price. The average brokerage recommendation is 2.0, indicating "Outperform" status.

Innoviva, Inc. (NASDAQ: INVA) reported its second quarter 2025 financial results, highlighting significant progress and achievements. The company's Chief Executive Officer, Pavel Raifeld, noted the strong performance from its GSK royalties portfolio and the momentum from its IST-marketed products, including the successful launch of ZEVTERA, the first and only FDA-approved cephalosporin for MRSA-related Staphylococcus aureus bacteremia in the U.S.

Key financial highlights include:

- Royalty Revenue: Gross royalty revenue from Glaxo Group Limited (GSK) was $67.3 million, a slight increase from $67.2 million in the second quarter 2024.
- Net Product Sales: Totaled $35.5 million, with U.S. sales increasing by 54% to $29.0 million, compared to $21.7 million in the second quarter 2024.
- Income from Operations: Decreased to $48.8 million from $54.7 million in the second quarter 2024, primarily due to non-recurring milestone payments and increased research and development costs for zoliflodacin.
- Net Income: Improved to $63.7 million, or $1.01 per share, compared to a net loss of $34.7 million in the second quarter 2024.
- Cash and Cash Equivalents: Totaled $397.5 million as of June 30, 2025.

Innoviva also made progress in its strategic healthcare asset portfolio, with positive Phase 2 data from Armata Pharmaceuticals’ recently announced study in Staphylococcus aureus bacteremia. The company's equity and long-term investments showed favorable changes of $24.4 million, primarily due to share price appreciation of Armata Pharmaceuticals and other equity investments.

Analysts at HC Wainwright & Co. have raised the price target for Innoviva to $45.00, a 12.50% increase from the prior target, and maintained its "Buy" rating. Analyst Raghuram Selvaraju expressed confidence in the company's market performance and growth potential. The average target price for INVA is $40.33, with a high estimate of $55.00 and a low estimate of $26.00, indicating a potential upside of 119.92% from the current price. The average brokerage recommendation is 2.0, indicating "Outperform" status.

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (IST), and a portfolio of strategic investments in healthcare assets. The company's royalty portfolio includes respiratory assets partnered with GSK, and its other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics and La Jolla Pharmaceutical Company.

References:
[1] https://www.marketscreener.com/news/innoviva-reports-second-quarter-2025-financial-results-highlights-recent-company-progress-ce7c5ededb8bf123